Léon Gosselin has announced a donation of a million dollars to the CHUM Foundation, to support a new research partnership for developing a next-generation personalized cancer vaccine.
“Two out of five Canadians are expected to develop cancer during their lifetime, and one out four Canadians is expected to die from cancer,” says Léon Gosselin. “What we have here is world‑class expertise that can bring us the oncology breakthroughs we so desperately need to fight this terrible disease.”
The partnership makes access to this new treatment approach possible by synergizing the technologies of the cancer stream of the CHUM Research Centre (CRCHUM), led by researcher Réjean Lapointe, and French-Canadian company ANGANY Inc., whose recently developed immunotherapy applications are a promising approach to vaccines as cancer treatment.
This generous donation to the CHUM Foundation will back the contributions of Réjean Lapointe and his CRCHUM team to this visionary project, which will bring hope to thousands of patients and families. Léon Gosselin’s initiative is the most recent in a series of donations to support his family foundation’s mission to drive and encourage new cancer treatment solutions.
In the words of Pascale Bouchard, President and Chief Executive Officer of the CHUM Foundation, “We are all affected by cancer in some way. The CHUM Foundation works to push the boundaries of healthcare, and the innovations and technological advances that will change the lives of cancer patients would not be possible without philanthropists like Léon Gosselin. We are so grateful for his support.”
More details will follow on the research partnership being developed.
